Search results
Results from the WOW.Com Content Network
By the end of 2010, the company had raised $75 million in financing over four rounds of funding. [19] The device received FDA clearance to be marketed for removing love handle fat from people's sides in September 2010 [20] and from the stomach in 2012. [20] It has also been approved by Health Canada and the European Union. [21]
Places That Hire at 14 Near Me Grocery Store Chains, retail stores, restaurants, recreation areas and more are all great places to look into for finding a job for young teenagers aged 14 to 16.
In May 2019, the US Food and Drug Administration (FDA) approved amifampridine tablets under the brand name Ruzurgi for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in people 6 to less than 17 years of age. This is the first FDA approval of a treatment specifically for pediatric patients with LEMS.
In 2010, guanfacine was approved by the FDA for the treatment of attention deficit hyperactivity disorder for people 6 to 17 years old. [16] It was approved for ADHD by the European Medicines Agency under the name Intuniv in 2015. [61] It was added to the Australian Pharmaceutical Benefits Scheme for the treatment of ADHD in 2018. [62]
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.
Kids Mineral Sunscreen. Think, a favorite of Dr. Maguiness, offers a kids sport sunscreen that's perfect for active summer days because its smooth formula goes on like a moisturizer.Thanks to the ...
According to pediatric endocrinology expert Brad Miller, pharmaceutical companies that make puberty blocker drugs for children with gender dysphoria have refused to submit them for FDA approval because doing so would cost too much money and "because (transgender treatment) was a political hot potato." [56]
DALLAS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the successful completion of an approximate $5.0 million equity financing in an at-the-market transaction.